Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04120363
Other study ID # PBRC 2019-017
Secondary ID W81XWH19C0162W81
Status Completed
Phase Phase 4
First received
Last updated
Start date September 23, 2019
Est. completion date July 8, 2021

Study information

Verified date September 2022
Source Pennington Biomedical Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the effects of a single dose of testosterone undecanoate during and in recovery from simulated operational stress.


Description:

This is a double-blind, randomized, placebo controlled trial in 32 physically active men exposed to 20 complete days (days 8-27) of simulated operational stress followed by 20 complete days of recovery (days 29-48). After completing baseline testing (Phase 1), participants will be randomized to receive either a single intramuscular injection of testosterone undecanoate or an isovolumetric placebo (Day 8). The 20-day simulated operational stress (Phase 2) will be highly controlled (live-in study) and consist of 4 successive cycles of undulating stress, starting with 2 consecutive days of low stress followed by 3 consecutive days of high stress. Low- and high-stress days will result from low and high militarily-relevant exercise-induced energy expenditures, adequate and restricted sleep (8 hours vs. 4 hours daily), and diet restriction to produce energy deficits. After completing Phase 2, participants will be released to resume their habitual physical activity routines and will be provided a controlled diet to consume (Phase 3), to assess recovery from sustained, severe operational stress.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date July 8, 2021
Est. primary completion date July 8, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Men aged 18-35 years - Ability to understand verbal or written instructions/testing materials in English - Physically active (as determined by accelerometry and review of a physical activity log) - Not taking any prescription medications and/or willing to refrain from all medication use prior to and throughout the entire study period, unless provided/approved by the study physician - Willing to refrain from alcohol, smoking, e-cigarettes or use of any nicotine product, caffeine, and dietary supplement use throughout the entire study period - Willing to live on the Pennington Biomedical Research Center inpatient unit for 20 consecutive days - Meets age-specific US Army body composition standards according to Army Regulation 600-9, which includes estimates of percent body fat based on height, weight, and circumference measures (neck and waist) - Total testosterone concentration is within the normal physiological range (300-1,000 ng/dL) Exclusion Criteria: - Musculoskeletal injuries that compromise exercise capability - Diagnosed cardiometabolic disorders (i.e., hypertension, hyperlipidemia, kidney disease, diabetes, etc.) - Allergies or intolerance to foods, vegetarian practices, or history of complications with lidocaine - Anabolic steroid, human growth hormone, or nutritional testosterone precursor-like supplement use within the past 6 months - Will not refrain from smoking (any nicotine product), alcohol, caffeine, or any other dietary supplement during the study - Adults unable to consent - Women - Prisoners - Sedentary or engages in insufficient quantities of physical activity per week (aerobic and/or resistance training as determined by accelerometry and review of a physical activity log) - Exceeds age-specific US Army body composition standards according to Army Regulation 600-9 - Previous history of kidney stones unless otherwise approved by the medical investigator - Systolic blood pressure > 150 or diastolic blood pressure > 95 mmHg - Previous history of breast or prostate cancer - Previous history of Chronic Obstructive Pulmonary Disease or Obstructive Sleep Apnea - Prostate-Specific Antigen (PSA) > 3ng/ml, Hematocrit > 50%, or positive urine drug screening - Based on the investigative team's clinical judgment, a subject may not be appropriate for participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Testosterone Undecanoate
single intramuscular injection of 750 mg testosterone undecanoate
Sesame Oil
single intramuscular injection of 750 mg sesame oil solution

Locations

Country Name City State
United States Pennington Biomedical Research Center Baton Rouge Louisiana

Sponsors (4)

Lead Sponsor Collaborator
Pennington Biomedical Research Center United States Army Research Institute of Environmental Medicine, United States Department of Defense, University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Load Carriage Time A load carriage time trial (a militarily relevant aerobic performance assessment) was conducted near the end of each study phase to assess aerobic performance. Day 5 (Phase 1), Day 26 (Phase 2), Day 47 (Phase 3)
Primary Vertical Jump Height Lower-body peak power was assessed near the end of each phase using a vertical jump test. Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
Primary Total Mass Lifted A 3-repetition maximum deadlift assessed muscular strength, endurance, and explosive power near the end of each study phase. Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
Primary Wingate Peak Power Anaerobic capacity was assessed using a Wingate anaerobic cycle test near the end of each study phase. Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
Primary Peak Aerobic Capacity Peak aerobic capacity was measured via treadmill VO2peak near the end of each study phase. Day 4 (Phase 1), Day 25 (Phase 2), Day 46 (Phase 3)
Secondary Body Composition A four-compartment (4C) model factoring in body mass, body volume, total body water, and bone mineral content was used to calculate fat-free body mass and fat mass at the end of each study phase. Day 7 (Phase 1), Day 28 (Phase 2), Day 49 (Phase 3)
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT04513743 - Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ N/A
Completed NCT03251274 - Bath Machine on Sleep Quality in Nursing Home N/A
Completed NCT04102345 - Lavender vs Zolpidem Sleep Quality During Diagnostic PSG Early Phase 1
Completed NCT03725943 - Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT04562181 - Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index N/A
Completed NCT05576844 - Ai Youmian (Love Better Sleep) for People Living With HIV N/A
Completed NCT05102565 - A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers N/A
Completed NCT04688099 - Synovial Fluid Sleep Study
Recruiting NCT04171245 - Prescribing Laughter for Sleep and Wellbeing in UAE University Students N/A
Completed NCT03758768 - The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms N/A
Completed NCT03163498 - Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
Completed NCT04093271 - Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep Phase 1
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Not yet recruiting NCT06455592 - Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years N/A